» Articles » PMID: 27129487

Patient-reported Barriers to Osteoporosis Therapy

Overview
Journal Arch Osteoporos
Publisher Springer
Date 2016 May 1
PMID 27129487
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose/introduction: Osteoporosis patients commonly cite treatment-related side effects, or the fear thereof, as a reason for discontinuing or not initiating anti-osteoporosis medications. The purpose of this study was to investigate, from the patient's perspective, reasons for (i) non-treatment of osteoporosis and (ii) discontinuation of osteoporosis therapy.

Methods: This was an internet-based survey of postmenopausal women in the USA who self-reported having been diagnosed with osteoporosis. Respondents were recruited from consumer research panels and received nominal compensation.

Results: Within the surveyed population (N = 1407), 581 patients were currently being treated, 503 had never been treated, and 323 had previously been treated. Among patients never treated for osteoporosis, the highest ranking reasons for non-treatment were the use of alternative treatments such as over-the-counter vitamins/supplements (57.5 % of respondents) and fear of side effects (43.9 %). Among previously treated patients, frequent reasons for discontinuation included the direction of the physician (41.2 % of respondents), concerns about long-term safety (30.3 %), and the experience of side effects (29.8 %). When asked about their willingness to restart their osteoporosis medication, previously treated patients who were not willing (N = 104) to restart had a higher frequency of experiencing side effects (44.2 versus 20.5 % of those willing; P < 0.001).

Conclusions: From the osteoporosis patient's perspective, barriers to prescription treatment include a preference for alternative, non-prescription treatments and a fear of possible side effects. Side effects are one of the most common reasons for discontinuing osteoporosis medications, and they appear to be associated with a lack of willingness to restart treatment.

Citing Articles

Nutraceuticals in osteoporosis prevention.

Roseti L, Borciani G, Grassi F, Desando G, Gambari L, Grigolo B Front Nutr. 2024; 11:1445955.

PMID: 39416651 PMC: 11479890. DOI: 10.3389/fnut.2024.1445955.


Healthcare professionals' perspectives and experiences of osteoporosis medication treatment: a qualitative systematic review.

Rezae F, Kelly A, Dey S, Moles R, Carter S Arch Osteoporos. 2024; 19(1):8.

PMID: 38191760 DOI: 10.1007/s11657-023-01359-y.


Improvement of proportion of days covered for denosumab under implementation of clinical pharmacist adherence management system: normal and COVID-19 period.

Yang Q, He J, Yuan F Osteoporos Int. 2023; 35(2):309-316.

PMID: 37801081 PMC: 10837216. DOI: 10.1007/s00198-023-06933-1.


Effect of Baduanjin exercise on primary osteoporosis: study protocol for randomized controlled trial.

Sun C, Chen M, Wang X, Qi B, Yin H, Ji Y BMC Complement Med Ther. 2023; 23(1):325.

PMID: 37716968 PMC: 10504697. DOI: 10.1186/s12906-023-04161-y.


Investigating the impact of a national educational program on patient adherence to osteoporosis medications.

Vuong T, Peters M, Merrifield A, Firipis M, Belcher J, Elgebaly Z Arch Osteoporos. 2023; 18(1):90.

PMID: 37405619 DOI: 10.1007/s11657-023-01301-2.


References
1.
Cosman F, de Beur S, LeBoff M, Lewiecki E, Tanner B, Randall S . Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int. 2014; 25(10):2359-81. PMC: 4176573. DOI: 10.1007/s00198-014-2794-2. View

2.
Watts N, Bilezikian J, Camacho P, Greenspan S, Harris S, Hodgson S . American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract. 2011; 16 Suppl 3:1-37. PMC: 4876714. DOI: 10.4158/ep.16.s3.1. View

3.
Wade S, Strader C, Fitzpatrick L, Anthony M, OMalley C . Estimating prevalence of osteoporosis: examples from industrialized countries. Arch Osteoporos. 2014; 9:182. DOI: 10.1007/s11657-014-0182-3. View

4.
Hollick R, Reid D . Role of bisphosphonates in the management of postmenopausal osteoporosis: an update on recent safety anxieties. Menopause Int. 2011; 17(2):66-72. DOI: 10.1258/mi.2011.011014. View

5.
Yun H, Curtis J, Guo L, Kilgore M, Muntner P, Saag K . Patterns and predictors of osteoporosis medication discontinuation and switching among Medicare beneficiaries. BMC Musculoskelet Disord. 2014; 15:112. PMC: 4022369. DOI: 10.1186/1471-2474-15-112. View